MOG Antibody-Associated Disorders Following SARS-CoV-2 Vaccination: A Case Report and Literature Review.

Matsumoto, Yuki; Ohyama, Ayane; Kubota, Takafumi; Ikeda, Kensuke; Kaneko, Kimihiko; Takai, Yoshiki; Warita, Hitoshi; Takahashi, Toshiyuki; Misu, Tatsuro; Aoki, Masashi

Matsumoto, Yuki; Ohyama, Ayane; Kubota, Takafumi; Ikeda, Kensuke; Kaneko, Kimihiko; Takai, Yoshiki; Warita, Hitoshi; Takahashi, Toshiyuki; Misu, Tatsuro; Aoki, Masashi.

Afiliación

Matsumoto Y; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.
Ohyama A; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Kubota T; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Ikeda K; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Kaneko K; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Takai Y; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Warita H; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Takahashi T; Department of Neurology, National Hospital Organization Yonezawa Hospital, Yonezawa, Japan.
Misu T; Department of Neurology, Tohoku University Hospital, Sendai, Japan.
Aoki M; Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan.

Front Neurol ; 13: 845755, 2022.

Article en En | MEDLINE | ID: mdl-35299613

Palabras clave

COVID-19; SARS-CoV-2; cerebellar peduncle; mRNA vaccine; myelin oligodendrocyte glycoprotein (MOG); post-vaccination

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Neurol Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google